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Article
Low Levels of Hemoglobin at Admission Are
Associated With Increased 30-Day Mortality
in Patients With Hip Fracture
Katrine Praetorius1, Christian M. Madsen, MD1,
Bo Abrahamsen, MD, PhD2, Henrik L. Jørgensen, MD, PhD3,
Jes B. Lauritzen, MD, DMSci1, and Anne Sofie B. Laulund, MD1
Abstract
Introduction: Previous smaller studies suggest that anemia is a risk factor for mortality in patients with hip fracture. The purpose
of this investigation was to assess the correlation between hemoglobin at admission with 30-day mortality following a hip fracture
in a large-scale study. Patients and Methods: From January 1996 to December 2012, all patients with hip fracture (>60 years of
age) admitted to Bispebjerg Hospital, Copenhagen, were identified from a local hip fracture database. We excluded conservatively
treated patients and patients who died preoperatively. Results: Seven thousand four hundred twenty-one consecutive patients
with hip fracture were identified. Of those 7319 had a hemoglobin measurement on admission and were thus eligible for further
analysis. Mean hemoglobin for patients alive at 30 days was 7.6 (standard deviation [SD]: 1.0) and for deceased patients 7.4
(SD: 1.1), P < .0001. Mean age was 82.6 years (SD: 8.5), and 76.5% of the population were female (Nfemales ¼ 5600). The 30-day
mortality decreases for every increase in hemoglobin of 1.0 mmol/L in a univariate analysis (P < .0001). The hazard ratio (HR) with
95% confidence interval (CI) for 30-day mortality in patients with anemia (<7.3 mmol/L for females and <8.3 mmol/L for males;
Nanemic ¼ 3235) was 1.66 (CI: 1.43-1.91, P < .0001). Adjusting for age, type of fracture, gender, and comorbidities (Charlson
score) slightly attenuated the risk estimate (HR: 1.21, CI: 1.03-1.41, P ¼ .02). Conclusion: This study demonstrates increased
30-day mortality in patients with low hemoglobin at admission, even after adjusting for comorbidities.
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Introduction
Osteoporosis is diagnosed in 21% of all women and 6% of all
men between 50 and 84 years, and the lifetime risk of any of the
most common fractures due to osteoporosis is estimated to be
46% for women and 22% for men aged 50 or above. The life-
time risk of hip fracture is estimated to count for more than half
of these, 23% in women and 11% in men. This results in a
prevalence of 3.5 million fractures per year worldwide.1
The postoperative comorbidity and complications, such as
urinary tract infections, cardiac problems, pressure ulcers, deep
venous thrombosis, and pneumonia,2,3 make the patients a
high-risk group in regard to mortality. This is well established
in the previously published literature, where 1-year mortality
rates are shown to be between 17% and 35%.4-9
Given the global increase in life expectancy,10 the preva-
lence of hip fractures has been estimated to reach 4.5 million
worldwide in 2025.1 Worldwide indirect and direct costs are
estimated to be US$131.5 billion by 2050,11 due to the sub-
stantial rehabilitation, postoperative hospitalization, and
complications.
Because of this expected increase in costs, both in economic
terms and in human lives, it is important to pinpoint where
intervention from the clinician will be the most effective. This
can be done through investigation of the impact of different
factors on the outcome following a hip fracture. Some factors
are nonmodifiable, such as age, gender, type of fracture, her-
editary disposition, and comorbidities preoperatively and post-
operatively, whereas others are modifiable and the ones that
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need increased attention. The modifiable factors include phys-
ical health, nutrition status, body mass index (BMI), alcohol
abuse, sex hormone status, high serum creatinine, low serum
albumin, low hemoglobin, pharmacological interventions/
comedications (eg, glycocorticoid therapy), time period from
fracture to surgery, postsurgery care (eg, institution type), and
so on.
Blood tests are stable, easily interpreted, and relatively inex-
pensive tests. Routine blood tests taken at admission can there-
fore be a potentially easy way to identify patients at increased
risk of dying.
The influence of low hemoglobin levels on mortality in
patients with hip fracture has been examined by several smaller
studies with limited or no information on comorbidities, and
the results pooled in a meta-analysis show excess mortality in
patients with low hemoglobin.12
The aim of this study was therefore to investigate the asso-
ciation of low hemoglobin levels with 30-day mortality in
patients with hip fracture in a larger setting, with the possibility
of adjusting for comorbidities.
Patients and Methods
Data Sources
The study population was identified in a local database of all
surgically treated patients with hip fracture at Bispebjerg
Hospital.
Data were subsequently collected from different resources
using the social security number. Patient information was anon-
ymized and deidentified prior to analysis.
The databases included were the Danish Civil Registration
System (DCRS) and the Danish National Patient Register
(DNPR). The DCRS includes all habitants of Denmark. Each
person receives a unique identity number, which functions as
identification and a social security number. The DCRS stores
personal information such as name, address, marital status,
place of birth, citizenship, kinship (parents/children), declara-
tion of incapacity, profession, voting rights, municipal circum-
stances, registration notes, and death.13 Information from
DCRS was combined with information from the DNPR (see
Figure 1). The DNPR contains data from all Danish somatic
hospitals since 1977. Since 1994, the diagnoses have been
coded according to the International Classification of Dis-
eases, 10th Revision (ICD-10).14
Study Patients
The initial extraction from the local hip fracture database
included all surgically treated patients admitted to Bispebjerg
Hospital with a fractured hip (femoral neck fracture [57%]
ICD-10 code DS720, intertrochanteric femoral fracture [37%]
ICD-10 code DS721, and subtrochanteric fracture [6%] ICD-10
code DS722) between January 1996 and December 2012 and
aged 60 years or above. Patients treated conservatively and
patients who died preoperatively were not included. Seven
thousand four hundred twenty-one patients were identified
from the database. The hospital laboratory information system
was searched for available admission hemoglobin levels (def-
inition: first preoperative hemoglobin measurement following
admission and no later than 2 days after admission). Seven
thousand three hundred nineteen (98.6%) patients had an
admission hemoglobin measurement and comprised the final
study cohort.
Comorbidity
The Charlson comorbidity index (CCI) was applied to mea-
sure the burden of disease and thus enabling confounder
adjustment of the results. The index is based on 22 clinical
conditions (myocardial infarct, congestive heart failure, per-
ipheral vascular disease, dementia, cerebrovascular disease,
chronic lung disease, connective tissue disease, ulcer, chronic
liver disease, diabetes, hemiplegia, moderate or severe kidney
disease, diabetes with or without organ damage, tumor, leu-
kemia, lymphoma, moderate or severe liver disease, malig-
nant tumor, metastasis, and AIDS). Each condition is given an
associated weight (1, 2, 3, and 6) according to the gravity of
the disease.15
Using the ICD-10 coding algorithm by Quan et al,16 disease
categories were identified from DNPR. The CCI was applied to
hospital contacts in the time period from the beginning of
January 1977 (establishment of DNPR) until the end of the
study, December 2012.
Biochemical Measurements
Anemia was defined as a hemoglobin level below 7.3 mmol/L
for women and below 8.3 mmol/L for men at admission, in
accordance with the reference intervals for hemoglobin at the
Department of Clinical Biochemistry, Bispebjerg Hospital.
Figure 1. Databases included in the study used to combine and
identify information about each patient.
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Hemoglobin was analyzed using photometric methods.
Throughout the study period, the Department of Clinical
Biochemistry has participated in external quality assurance
programs assuring stable levels.
Statistics
Data analysis was performed using SAS version 9.3 (2011;
SAS Institute Inc, Cary, North Carolina) through virtual private
network access to Statistics Denmark. The outcome was
defined as 30-day mortality. Differences between baseline val-
ues of the 2 groups were analyzed using parametric, nonpara-
metric, or categorical statistical methods depending on data
nature. Categorical data were analyzed using Pearson w2 test,
and differences between continuous data were compared using
unpaired t tests for normally distributed variables and Mann-
Whitney U tests for nonnormally distributed variables. Signif-
icant differences between the 2 groups were defined as a
P value below .05 with 2-tailed tests.
Cox proportional hazards models were used to determine
hazard ratios (HRs) for 30-day mortality. Hazard ratios were
adjusted for confounders, including age, gender, and comorbid-
ities (CCI). Potential violations of the proportional hazards
assumption were evaluated by visual inspection of Schoenfeld
residuals over time and did not occur.
Approvals
This study was approved by the data protection agency (j.nr.:
2012-58-0004.)/local number BBH-2014-050 and by Statistics
Denmark (project number 704670).
Results
Basic Characteristics
Of the 7319 included patients, anemia was observed in 3142
(42.9%) individuals. The mean hemoglobin level for patients
alive at 30 days was 7.6 (standard deviation [SD]: 1.0) and for
deceased patients 7.4 (SD: 1.1), P < .0001. The mean age of
this population was 82.6 years (SD: 8.5). The majority of the
7319 patients were women 5600 (76.5%). The basic character-
istics of the population are summarized in Table 1.
Thirty-Day Mortality
The 30-day mortality for patients with anemia was 13.0% and
for nonanemic patients 8.1% (P < .0001). The 30-day mortality
decreases for every increase in hemoglobin of 1.0 mmol/L in a
univariate analysis (P < .0001), indicating a dose-dependent
correlation with mortality (see Figure 2).
The HR with 95% confidence interval (CI) for 30-day mor-
tality in patients with anemia was 1.65 (CI: 1.43-1.91,
P < .0001). Adjusting for age, type of fracture, gender, and
comorbidities (CCI) slightly attenuated the risk estimate (HR:
1.21, CI: 1.03-1.41, P ¼ .02; see Figure 3).
Discussion
The excess mortality in patients with hip fractures compared
with the general population is well established.4-7,9 In fact, the
excess mortality is similar to the 1-year mortality observed for
advanced colon cancer.17,18 Different factors have been asso-
ciated with this high mortality. In this Danish register-based
study based on biochemical data from 7319 individuals with
hip fractures, we demonstrated an increased mortality in indi-
viduals with a hemoglobin measurement below the reference
range.
Previous studies19-25 have examined the same association
between anemia and mortality in patients with hip fracture, and
the pooled results show excess mortality in patients with low
hemoglobin.12 However, these studies had a relatively low num-
ber of patients (the highest with 552 patients20). In addition, the
cutoff values are not uniform, ranging from 6.21 to 8.07mmol/L.
This fact limits the validity of pooling the results.12
In contrast to this, our study has a relatively large cohort,
which gives it a high statistical power. In addition, this study
was a single-center study with a single biochemistry testing
facility, which minimizes issues with different procedure at
different locations.
The factors affecting postoperative mortality can overall be
divided into 2 categories: (1) complications derived from pre-
existing conditions and (2) complications directly associated
with the trauma and treatment. To compensate for the first
category, we used previously validated methods to adjust for
comorbidities. Despite this, it must be noted that the CCI does
not take BMI, smoker, alcohol abuse, or the preoperative func-
tional status into account. Several previously published studies
have concluded that these have considerable confounding
effect on postoperative outcome.26,27 Unfortunately, these data
were not available for the present study.
Table 1. Basic Characteristics According to 30-Day Survival and
Mortality.
Alive at 30 days Dead at 30 days P value
Number 6574 745 NA
Female (%) 5120 (77.9%) 480 (64.4%) <.0001
Mean age (SD) 82.2 (8.4) 85.9 (7.7) <.0001
CCI, median (range) 1 (0-15) 1 (0-13) <.0001
CCI, n (%)
0 2695 (41.0%) 222 (29.8%) <.0001
1 1543 (23.5%) 173 (23.2%)
2 1074 (16.3%) 142 (19.1%)
3 1262 (19.2%) 208 (27.9%)
Fracture type
Missing 12 (0.2%) 2 (0.3%) .6
Femoral neck (1) 4341 (66.0%) 474 (63.6%)
Pertrochanteric (2) 1953 (29.7%) 236 (31.7%)
Subtrochanteric (3) 268 (4.1%) 33 (4.4%)
Mean hemoglobin (SD) 7.6 (1.0) 7.4 (1.1) <.0001
Anemia (%) 2734 (41.6%) 408 (54.8%) <.0001
Abbreviations: CCI, Charlson Comorbidity Index; NA, not applicable; SD,
standard deviation.
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The second category includes modifiable factors and thereby
the opportunity to optimize individual treatment. Studies investi-
gating these factors with specific protocols to optimize outcome
show improved walking on discharge,28 reduced hospitalization
time,29,30 and significant reductions in the 30-day mortality.29
Another important factor is the length of time before
surgery. It is known to be very central for the survival of
patients with hip fracture. This is demonstrated in a study
from 2005 by Moran et al, which shows that increased
mortality is associated with a delay in surgery for more than
Figure 3. Hazard ratios for 30-day mortality determined with Cox proportional hazards models.
Figure 2. The 30-day mortality decreases for every increase in hemoglobin of 1.0 mmol/L in a univariate analysis (P < .0001).
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4 days,31 and in a study from Denmark, which demonstrates
an increased 30-day mortality of 24% with each 24-hour
surgical delay.32 Information about surgical delay was
unfortunately not available in this study and has therefore
not been taken into account.
Hemoglobin level is another potentially modifiable factor,
and the measurement has the advantage of being a stable, easily
interpreted, and relatively inexpensive test. Our study clearly
shows an increased mortality in patients with low hemoglobin
level at admission. Intervention such as transfusion and nutri-
tional therapy might be optimizing interventions. There is con-
siderable disagreement about the benefit of transfusion. One
study from 2011 conducted a randomized trial to investigate
the benefit of a postoperative liberal transfusion strategy in
patients with hip fractures, but they did not prove any benefit.33
In addition, many side effects are linked to blood transfusion.34
Further studies are therefore needed to investigate this possi-
bility. One thing that we can conclude is that with a hemoglobin
measurement, at-risk patients can be identified and further
interventions can be instituted.
Conclusion
This study demonstrates increased 30-day mortality in patients
with low hemoglobin, even after adjusting for comorbidities.
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